Source:http://linkedlifedata.com/resource/pubmed/id/12581574
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2003-2-12
|
| pubmed:abstractText |
A phase II multicentre study of a 3-week schedule of irinotecan (CPT-11) and cisplatin providing the highest recommended dose intensity of both agents in combination, was conducted in patients with advanced non-small cell lung cancer (NSCLC). Seventy-four stage IIIB (not suitable for radiotherapy) or stage IV NSCLC patients were enrolled to receive CPT-11 200 mg/m(2) i.v. and cisplatin 80 mg/m(2) i.v. on day 1 every 3 weeks. Relative dose-intensities for CPT-11 and cisplatin were 92 and 95%, respectively. No complete responses were observed. Twenty-five patients out of 73 obtained a partial response (34.2%). Partial responses were confirmed in 18 patients (24.7%: 95% CI, 15.3-36.1%). Median survival overall was 8.2 months, 9.7 months for patients with baseline performance status (PS) 0 and 1, and 4 months for patients with PS 2. The 1-year survival rate was 31%. Major clinical toxicities were grade 3 and 4 delayed diarrhoea (29% of patients) and febrile neutropenia (14% of patients). In conclusion, the present once-every-3-week schedule of CPT-11 and cisplatin is feasible and active in PS 0-1 advanced NSCLC patients, but results do not seem superior to those reported with other schedules.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0169-5002
|
| pubmed:author |
pubmed-author:ArtalAA,
pubmed-author:BalcellsMM,
pubmed-author:BarnettFF,
pubmed-author:CardenasII,
pubmed-author:CarratoAA,
pubmed-author:DomineMM,
pubmed-author:FelixMM,
pubmed-author:GarridoPP,
pubmed-author:HullJ PJP,
pubmed-author:López-VivancoGG,
pubmed-author:MassutíBB,
pubmed-author:RosellRR
|
| pubmed:copyrightInfo |
Copyright 2002 Elsevier Science Ireland Ltd.
|
| pubmed:issnType |
Print
|
| pubmed:volume |
39
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
201-7
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:12581574-Adenocarcinoma,
pubmed-meshheading:12581574-Adult,
pubmed-meshheading:12581574-Aged,
pubmed-meshheading:12581574-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12581574-Camptothecin,
pubmed-meshheading:12581574-Carcinoma, Large Cell,
pubmed-meshheading:12581574-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:12581574-Carcinoma, Squamous Cell,
pubmed-meshheading:12581574-Cisplatin,
pubmed-meshheading:12581574-Dose-Response Relationship, Drug,
pubmed-meshheading:12581574-Drug Administration Schedule,
pubmed-meshheading:12581574-Female,
pubmed-meshheading:12581574-Humans,
pubmed-meshheading:12581574-Lung Neoplasms,
pubmed-meshheading:12581574-Male,
pubmed-meshheading:12581574-Middle Aged,
pubmed-meshheading:12581574-Neoplasm Staging,
pubmed-meshheading:12581574-Survival Rate,
pubmed-meshheading:12581574-Treatment Outcome
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study.
|
| pubmed:affiliation |
Medical Oncology Department, Institut Català d'Oncologia, Av. Gran Via s/n, km 2.7, 08907 L'Hospitalet, Barcelona, Spain. fcardenal@csub.scs.es
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study,
Clinical Trial, Phase II
|